First new diet pill in 13 years approved by FDA

By Catholic Online (NEWS CONSORTIUM)
6/28/2012
Catholic Online (www.catholic.org)

'Belviq' enters a market where many users discard after brief use

Called Belviq, the first new prescription diet pill in 13 years has won approval from the Food and Drug Administration. While the medication is intended to help roughly one-third of American adults who are considered obese, Belviq enters a pharmaceutical market where so-called "diet pills" have only enjoyed limited success.

Diet pills in the U.S. have faced a long and troubled history. There have been myriad safety problems and product withdrawals, which has made the F.D.A. reluctant to approve new drugs.

Facebook Delicous MySpace

Twitter Stumble Digg

More Destinations

LOS ANGELES, CA (Catholic Online) - Chief among the many challenges facing Belviq is the fact that many diet drugs do not sell that well as insurers often do not cover them.

Will people will use Belviq? In spite of an increasingly obese U.S. population, diet drugs have not sold well in the past partially because people tend to use them for only a short time.

Developed by Arena Pharmaceuticals of San Diego, Belviq has been known as lorcaserin. The drug will be sold under the name Belviq by Eisai Inc., the American branch of the Japanese pharmaceutical company.

Only one anti-obesity medicine had been approved for long-term use before Belviq's recent approval. Roche's Xenical, which reached the market in 1999 is rarely due to modest weight loss and unpleasant effects on the digestive system.

Diet pills in the U.S. have faced a long and troubled history. There have been myriad safety problems and product withdrawals, which has made the F.D.A. reluctant to approve new drugs.
Belviq itself was turned down by the agency in 2010, but Arena came back with new data that assuaged the agency's safety concerns.

Doctors who treat obesity say there is a need for new medicines to help to plug a "treatment gap" between diet and exercise, which do not work for many people, and the more radical option of bariatric surgery. Obesity is a serious health condition that causes other health problems like diabetes and heart disease.

The F.D.A. is sympathetic to these concerns. "Obesity threatens the overall well being of patients and is a major public health concern," Dr. Janet Woodcock, director of the drug evaluation center at the F.D.A., said in a statement.

Arena said it was not clear yet when the drug would be available to patients or how much it would cost. Because the F.D.A. deemed that there was some potential for the drug to be abused, the Drug Enforcement Administration must now decide what controls to place on prescribers, a process that Arena said could take four to six months.

� 2012, Catholic Online. Distributed by NEWS CONSORTIUM.

- - -

Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.

Keywords: Diet drugs, FDA, Belviq, obesity, doctors

NEWSLETTERS »

Rate This Article

Was this helpful to you? Very Helpful Somewhat Helpful Not Helpful at All

Would you be interested in more articles like this? Yes, I am Interested No, I am not Interested

Rate Article

0 Comments

Comments submitted must be civil, remain on-topic and not violate any laws including copyright. We reserve the right to delete any comments which are abusive, inappropriate or not constructive to the discussion.

Though we invite robust discussion, we reserve the right to not publish any comment which denigrates the human person, undermines marriage and the family, or advocates for positions which openly oppose the teaching of the Catholic Church.

This is a supervised forum and the Editors of Catholic Online retain the right to direct it.

We also reserve the right to block any commenter for repeated violations. Your email address is required to post, but it will not be published on the site.

We ask that you NOT post your comment more than once. Catholic Online is growing and our ability to review all comments sometimes results in a delay in their publication.

Name *

Email *

Comment *

Send me important information from Catholic Online and it's partners. See Sample

Post Comment